Learn more

BIOGEN INC

Overview
  • Total Patents
    1,329
  • GoodIP Patent Rank
    37,134
  • Filing trend
    ⇧ 800.0%
About

BIOGEN INC has a total of 1,329 patent applications. It increased the IP activity by 800.0%. Its first patent ever was published in 1979. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are BIOGEN IDEC INC, GENETICS INST and INST GENETICS LLC.

Patent filings per year

Chart showing BIOGEN INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Benjamin Christopher D 76
#2 Maraganore John M 75
#3 Lee Wen-Cherng 63
#4 Browning Jeffrey L 62
#5 Pepinsky R Blake 61
#6 Browning Jeffrey 58
#7 Lin Ko-Chung 56
#8 Wallner Barbara P 56
#9 Thomas David W 55
#10 Adams Steven P 55

Latest patents

Publication Filing date Title
WO2020210486A1 Processes for preparing alpha-carboxamide pyrrolidine derivatives
WO2019075073A2 Process for preparing spiro derivatives
AU2018346763A1 Process for preparing alpha-carboxamide pyrolidine derivatives
WO2019067961A1 Novel salts
EA028448B1 Method for reducing flu-like symptoms associated with treating a patient with multiple sclerosis and titration package for reducing flu-like symptoms associated with treating a patient with multiple sclerosis
AU2003277065A1 Systems for controlling injection rate through a hypodermic needle
AU2003270715A1 Improved methods for preparing highly active april ligand polypeptides
CN1694698A Pyrazolopyridines and methods of making and using the same
US2005118166A1 Therapeutic applications for the anti-T-BAM (CD40-1) monoclonal antibody 5C8
CN1678625A Humanized anti-lymphotoyin beta receptor antibodies
ZA200303347B Humanized anti-LT-beta-R antibodies.
US2003190307A1 Stable liquid interferon formulations
AU2003215298A1 Alpha1beta1 antagonists for treatment of atherosclerosis
WO03037260A2 Methods and compositions for treating parkinson's disease
CA2480119A1 Cripto-specific antibodies
IL158573D0 Cripto blocking antibodies and uses thereof
AU2920002A Treatment of lupus nephritis with Anti-CD40L compounds
YU61203A Methods for treating or preventing skin disorders using cd2-binding agents
UA75625C2 Condensed purine derivatives as a1 adenosine receptor antagonists
AU9133001A Cell adhesion inhibitors